Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 17, 2022

Obinutuzumab, Acalabrutinib, and Venetoclax After Optional Debulking With Bendamustine in Relapsed/Refractory CLL

The Lancet Haematology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Haematology
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
Lancet Haematol 2022 Aug 18;[EPub Ahead of Print], P Cramer, M Fürstenau, S Robrecht, A Giza, C Zhang, AM Fink, K Fischer, P Langerbeins, O Al-Sawaf, E Tausch, C Schneider, J Schetelig, P Dreger, S Böttcher, KA Kreuzer, A Schilhabel, M Ritgen, M Brüggemann, M Kneba, S Stilgenbauer, B Eichhorst, M Hallek

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading